title: Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool.
abstract: OBJECTIVE
  This work was designed to explore the ability of the self-administered Overactive Bladder 8-Question Awareness Tool (OAB-V8) to predict patient self-assessed effectiveness of antimuscarinic therapy on OAB symptoms in daily practice. Also, the ability of the tool to predict clinician evaluation of improvement was explored.
  
  
  METHODS
  Patients of both genders, >18 years, with symptomatic OAB (score >8 on OAB-V8), and able to understand patient-reported outcome instruments were enrolled in this 3-month study. Patients were prescribed treatment with an antimuscarinic drug according to usual practice. Treatment effectiveness was assessed by the clinician and patient using the Clinical Global Impression of Improvement and Treatment Benefit Scale and by improved self-perceived quality of life using the Overactive Bladder Questionnaire Short Form (OAB-q SF) 3 months after initiating or changing an antimuscarinic therapy. Multivariate linear and logistic regression models were applied to explore the predictive validity of OAB-V8 scores at the baseline visit.
  
  
  RESULTS
  A total of 246 patients (57.7 years, 67 % women) were analyzed. Based on baseline OAB-V8 scores, logistic regression models were capable of predicting clinical improvement and patient self-perceived treatment benefit in 70 % of cases. OAB-V8 scores significantly correlated with OAB-q SF domains at baseline: 0.790 and - 0.659 for symptom bother and health-related quality of life domains, respectively (p < 0.001 in both cases). Baseline OAB-V8 score was able to predict changes in both domains of the OAB-q SF: R (2) = 0.212 and 0.162 for symptom bother and health-related quality of life, respectively.
  
  
  CONCLUSIONS
  The OAB-V8 scale showed evidence of predictive validity for antimuscarinic effectiveness in daily practice based on physician assessment and patient self-assessment of improved quality of life and treatment benefit.
authors.affiliation: Department of Urology, Hospital 12 de Octubre, Avda de Córdoba s/n, 28041 Madrid, Spain. FVILLACAMPA@telefonica.net
authors.forename: Felipe
authors.initials: F
authors.lastname: Villacampa
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Ruiz
authors.forename: Carlos
authors.initials: C
authors.lastname: Errando
authors.forename: Salvador
authors.initials: S
authors.lastname: Arlandis
authors.forename: Daniel
authors.initials: D
authors.lastname: Arumí
authors.forename: Isabel
authors.initials: I
authors.lastname: Lizarraga
authors.forename: Javier
authors.initials: J
authors.lastname: Rejas
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D059026:Diagnostic Self Evaluation; D005260:Female; D006801:Humans; D016014:Linear Models; D016015:Logistic Models; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011795:Surveys and Questionnaires; D053201:Urinary Bladder, Overactive / Q000175:diagnosis* / Q000188:drug therapy; D014572:Urology / Q000379:methods*; D055815:Young Adult
chemical_list: D018727:Muscarinic Antagonists